Condition

Pancreas Adenocarcinoma

ClinicalTrials.gov condition label

Clinical trials7

Recruiting3

Common interventions7

Lead sponsors shown7

Clinical trials

7 shown

THE-0504 in Patients With Solid TumorsNCT07646106 · 2024-11-13

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid TumorsNCT06451497 · 2024-05-22

Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor PrognosisNCT06160596 · 2023-11-01

A Study of IMM-6-415 in RAS/RAF Mutant Solid TumorsNCT06208124 · 2024-02-27

A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid TumorsNCT05784597 · 2023-04-27

The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the ElderlyNCT04164602 · 2019-10-09

A Study of ASN007 in Patients With Advanced Solid TumorsNCT03415126 · 2018-01-19

Common interventions

[68Ga]Ga-OncoFAP administrationDRUG1 ASN007 RDDRUG1 ASN007: ascending dosesDRUG1 IMM-6-415DRUG1 Long term survival multimodal analysisGENETIC1 THE-0504DRUG1 ZM008BIOLOGICAL1

Leading sponsors

Asana BioSciences1 Cure 511 Immuneering Corporation1 Philogen S.p.A.1 Thena Biotech S.r.l.1 University of Pecs1 Zumutor Biologics Inc.1

Trial status mix

COMPLETED3

RECRUITING3

UNKNOWN1

Phase mix

PHASE15

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.